💊
Pharmaceuticals
Données simuléesLaboratoires pharmaceutiques et médicaments.
Actions couvertes
16
WorldInvest Score moyen
43
Performance moy. 1A
+19.4%
Top 20 Pharmaceuticals Stocks
Voir le classement →| # | Entreprise | Pays | Prix | 1D | Cap. | Score | Mom. | Growth | Risque |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Novo NordiskNVO | DK | DKK 120.00 | +2.30% | 500.0B | 77 | 64 | 93 | Medium |
| 2 | Eli LillyLLY | US | $880.00 | +1.47% | 800.0B | 67 | 49 | 85 | Medium |
| 3 | GSKGSK | GB | £40.00 | +0.65% | 80.0B | 51 | 68 | 14 | Low |
| 4 | NovartelNVT | CH | CHF 89.20 | +1.55% | 210.0B | 46 | 61 | 14 | Low |
| 5 | NovartisNOVN | CH | CHF 105.00 | -2.41% | 220.0B | 44 | 44 | 20 | Low |
| 6 | AbbVieABBV | US | $170.00 | -1.81% | 300.0B | 43 | 38 | 6 | Low |
| 7 | AstraZenecaAZN | GB | £78.00 | +0.56% | 240.0B | 42 | 22 | 100 | High |
| 8 | PfizerPFE | US | $28.00 | +0.21% | 160.0B | 40 | 42 | 7 | Medium |
| 9 | RochetRCH | CH | CHF 262.00 | +2.97% | 240.0B | 40 | 40 | 10 | Low |
| 10 | Merck & Co.MRK | US | $125.00 | -0.68% | 320.0B | 40 | 25 | 35 | Low |
| 11 | BayerBAYN | DE | €28.00 | -2.58% | 30.0B | 39 | 47 | 10 | Medium |
| 12 | Takeda PharmaceuticalTAK | JP | ¥14 | -1.88% | 45.0B | 36 | 46 | 13 | Medium |
| 13 | SanoforSNO | FR | €96.50 | +0.10% | 130.0B | 36 | 60 | 1 | Medium |
| 14 | Johnson & JohnsonJNJ | US | $160.00 | -0.72% | 400.0B | 31 | 25 | 8 | Medium |
| 15 | BayerionBAY | DE | €27.10 | -0.20% | 55.0B | 28 | 35 | 14 | High |
| 16 | PfizorPFE2 | US | $28.30 | -2.97% | 160.0B | 26 | 24 | 8 | High |
🚀 Top Growth
- 1Novo Nordisk85
- 2Eli Lilly76
- 3AstraZeneca65
- 4Merck & Co.35
- 5GSK34
📈 Top Momentum
- 1Novo Nordisk76
- 2GSK60
- 3Eli Lilly60
- 4Novartel51
- 5Sanofor43
💵 Top Dividend
- 1AbbVie61
- 2Novo Nordisk61
- 3Eli Lilly58
- 4Novartel56
- 5Rochet55